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Galectin-1 helps in HIV-1 pathogenesis by interaction between viral capsid protein gp120 
and CD4 protein of susceptible helper T cell. Therefore, strategy to identify inhibitor for 
Galectin-1 will be of much importance in medical research. Here, structure based 
pharmacophore modelling, pharmacophore based screening, molecular docking, protein–
ligand interaction fingerprints, binding energy calculations, and Quantitative Structure-
Activity Relationship (QSAR) predictions were employed in a virtual screening strategy to 
identify novel inhibitors. A structure-based pharmacophore model was hypothesized that 
contained 6 pharmacophoric features as observed in crystal structure of galectin-1 and its 
inhibitor thiodigalactoside. The pharmacophore model was used to screen NCI, open 
database compounds release4 with 2, 46,374 active molecules. A total of 2233 hits were 
obtained from NCI database. The hits retrieved were further screened by molecular docking, 
protein–ligand interaction fingerprints, binding energy calculations. After that we predicted 
IC50 values of screened molecules. Based on these results, 6 molecules were predicted as 
potential inhibitors of galectin-1.  
Key words: Galectin-1, HIV-1, Structure based phramacophore modelling, Molecular 
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      Human deficiency Virus (HIV)-1 is responsible for Acquired Immunodeficiency 
Syndrome (AIDS), and more than 25 million causality has been reported [1]. Cell 
mediated endocytosis helps HIV-1 to enter body cell. Susceptible helper T lymphocytes 
(TH), target for HIV-1 entry express high level of CD4 protein on cell surface. The 
perquisite of HIV-1 is the infection of TH cells by binding on to CD4 protein and so, it is 
called Lymphotrophic. Other kind of cells that binds HIV-1 virus includes macrophages, 
monocytes, dendritic cells, Langerhans cells, haematopoietic stem cells, certain rectal 
lining cells and microglial cells etc. These cells weakly bind to the virus particle than TH 
lymphocyte because of low expression of CD4 proteins on the latter cell surface [2-4].  
        Adherence of virus to target CD4 cell occurs via specific interactions between the 
viral envelope glycoprotein (gp120) and the amino terminal immunoglobulin domain of 
CD4 protein. These interactions are enough for binding but are not sufficient for 
infection. So they expect additional cell surface proteins for initiating further fusion 
process of viral and target cell membrane [5]. Unlike other enveloped viruses, HIV-1 
carries a limited number of envelop spikes, which are required for its adsorption to target 
cells [6, 7]. HIV-1 is supposed to circumvent this limiting element by exploiting the 
host’s membrane adhesion molecules or soluble proteins that can promote attachment of 
viral particles to target cells [8-15, 17, 18]. One of the host molecules exploited by HIV-
1 is galectin-1, that has been reported to enhance both HIV-1 binding and infectivity in 
CD4+T cells and macrophages by increasing viral adsorption to target susceptible cells 
[14-16]. Since galectin-1 is profusely discovered in organs rich in CD4+ T cells, such as 
lymphoid tissues and tissues encompassing the lamina propria of the genital and gut 
mucosa [19-21], it may act as a significant role in HIV-1 transmission. Thus, specific 
inhibition of galectin-1 could exemplify an interesting approach to chemically interfere 
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with HIV-1 propagation and to maximize the efficacy of HIV-1 attachment/entry 
inhibitors. 
Galectins are soluble glycan-binding proteins holding one or two carbohydrate 
recognition domains (CRDs), specified by conserved peptide sequences of approximately 
130 amino acids that are responsible for their β-galactoside-binding [22]. In spite of the 
similarity of their CRDs, each galectin exhibits a unique ligand preference that depends 
on the β-galactoside structure as well as its substitutions [23]. For example, galectin-3, as 
opposed to galectin-1, does not bind very efficiently to HIV-1 or its primary cellular 
receptor, CD4 [16, 17]. This indicates a specific interaction between galectin-1 and HIV-
1, which could be relevant for AIDS pathogenesis. So far, 15 galectins have been 
identified in mammals. Classification of galectins relies on the structural presentation of 
their CRD (i.e., prototype, chimera, and tandem repeated [24, 25]. For example, galectin-
1 is a prototype galectin, while galectin-4 is a member of the tandem-repeat type and 
galectin-3 is the sole representative of the chimera type.  
 In the context of HIV-1, it has been reported that galectin-1 is competent to cross-link 
molecules found on the exterior of both virions and target cells, thus consequence in a 
significant enhancement of HIV-1 infection [14-17]. Due to the characteristic ability of 
galectin-1 to specifically bind to clustered complex type glycans on HIV-1 and increase 
virus infectivity [16]. New inhibitors that interfere with galectin-1-mediated interactions 
could be clinically applicable and the look for a specific inhibitor for galectin-1 carry on.  
Therefore, we achieved to find synthetic compounds derived from the lactoside or 
galactoside molecule that could peculiarly inhibit galectin-1 activity in a cellular model 
of HIV-1 infection by altering their attached aglycone structures of lactoside or 
galactoside. While lactose has been used to inhibit galectin's activities in many probes, it 
is known to target every β-galactoside binding lectin and requires high concentrations (at 
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least 10 mM) to be effective. Variations in aglycone structures, which modify the charge 
density or multivalency of lactoside derivatives, allow lactosides to have more stable and 
specific interactions with the CRDs of selected galectins [57]. 
 
1.2 OBJECTIVES: 
To find potential inhibitors of Galectin-1 using structure-based virtual screening 
methods and also predict inhibitory concentration (IC50) of leads. 
1. To develop a small molecules database 
2. To generate structure based pharmacophore model 
3. To screen compound database with pharmacophore hypothesis 
4. To prepare protein target using GROMACS 
5. To perform molecular docking analysis with hits 
6. To generate and validate QSAR model 
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2.1 Human Immunodeficiency Virus (HIV): 
The acquired immune deficiency syndrome (AIDS) was first reported in patients in the 
USA in 1981. Later characterization of the principal causative agent, human 
immunodeficiency virus type 1 (HIV-1), uncovered that it was a retrovirus. As strains of 
HIV-1 were sampled from around the world, it became manifest that they exhibit 
extremely high genetic heterogeneity and that analysis of the evolution of this diversity 
can reveal insights into the prehistory of the virus [26].  
During HIV-1 was first described, the closest known relative was visna, a virus from 
sheep that is the prototypic member of the genus Lentivirus. After that lentiviruses were 
soon found in other primates, and a second virus (HIV-2) was found tainting humans. 
The viruses from non-human primates were named simian immunodeficiency viruses 
(SIVs). Among the first species incurred to be naturally infected were African green 
monkeys (Chlorocebus species), where the preponderance of infection is much more 
(greater than 50% of adults) and natural infections appear to be non-pathogenic. The 
number of different SIVs distinguished has increased steadily over the past 20 years. 
Presently, around 40 different primate species have been discovered to harbour SIVs, 
though information regarding prevalence and pathogenicity is lacking for most. So far, 
SIVs have only been found naturally infecting primates in sub-Saharan Africa, though the 
extent to which Asian or new world primates have been reviewed is unclear. Where 
multiple strains of SIVs have been characterized from a single species, they mostly form 
a monophyletic clade, suggesting that the great majority of transmissions are 
intraspecific. The primate viruses as a entire, including HIV-1 and HIV-2, form a distinct 
clade within the lentiviruses, showing that humans acquired their infections from other 
primates [27]. Phylogenetic analyses of these primate lentiviruses have provided 
outstandingly detailed insights into the evolutionary origins of the human viruses. 
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2.2 Life Cycle of HIV 1: 
The HIV-1 transmission action [28] is inducted by the binding of the viral envelope 
glycoprotein complex (Env; gp120, and gp41) to CD4, which is found on the surface of 
susceptible cells (Fig. 1-1). The transmembrane constituent of the envelope protein, 
gp41, can then initiate fusion of the viral membrane with the plasma membrane of the 
host cell. After fusion and transfer of the viral capsid in the cytoplasm, decapsidation 
directs to the release of viral enzymes, proteins, and genomic RNA inside the cell (Fig. 
1-2, Fusion). Reverse transcription of the viral genomic single-stranded positive RNA is 
then initiated to yield a double-stranded proviral DNA to be imported in the nucleus and 
integrated into host chromosome (Fig. 1-3 and 1-4, Reverse Transcription and 
Integration). 
 




2.3  Role of Host Molecules in HIV 1 Infection: 
HIV-1 is so recognized by dendritic cells (DCs) and Langerhans cells (LCs) via 
particular C-type lectins, such as DC-specific ICAM3-grabbing non-integrin (DC-SIGN), 
DC immune-receptor (DCIR), and Langerin [9, 11, 46]. DC-SIGN is extremely 
expressed in monocyte-derived DCs and dermal and mucosal DCs but not in LCs [47]. 
DC-SIGN binds to oligomannose-type glycans of gp120 and helps both direct infection 
of DCs (cis-infection) as well as DC-mediated HIV-1 transfer toward CD4+ T cells 
(trans-infection) [9, 48]. DCIR is expressed in antigen presenting cells, including 
myeloid and plasmacytoid DCs, also macrophages, but very few in LCs [49]. This lectin 
has recently been suggested to be related in both cis- and trans-infection by HIV-1 using 
monocyte-derived DCs [11].   
Instead of C-type lectins, two classes of host proteins, integrins and syndecans, are 
known to help HIV-1 infection. Two integrin family members, α4β7 and αLβ2 are listed 
as leading HIV-1 entry into susceptible cells. CD4+ T cells express αLβ2 (LFA-1), 
which promotes HIV-1 attachment by binding to ICAM-1, an adhesion molecule adopted 
by HIV-1 during the budding process. [50-52]. One more family that promotes HIV-1 
pathogenesis is syndecans [51]. Syndecans belong to a class of proteoglycans that 
contain covalently linked, heparan sulfate glycosaminoglycans, to which gp120 directly 
attaches [53, 54]. In fact, HIV-1 retains its infectivity for as long as a week when bound 
to cell-surface syndecans and can be readily transmitted upon contact with CD4+ T cells 
[46, 53, 54]. In addition to these host membrane bound proteins, the host soluble lectin 
galectin-1 also imparts to HIV-1 binding to CD4+ susceptible cells and promotes HIV-1 
infection [14-17, 56] (Figure 2). 




2.4  Galectins: 
Galectins are a phylogenetically conserved family of lectins explained in 1994 as a shared 
consensus of amino-acidsequences of about 130 amino acids and the carbohydrate 
recognition domain (CRD) responsible for β-galactoside binding [22]. Fifteen 
mammalian galectins have been recognized to date. While some of these galectins have 
one CRD and are biologically active as monomers (galectins-5, -7, -10), as homodimers 
(galectins-1, -2, -11, 13–14, -15) or as oligomers that aggregate though their non-lectin 
domain (galectin-3); others contain two CRDs connected by a short linker peptide 
(galectins-4, -6, -8, -9, -12). While the CRDs of all the galectins contribute an affinity for 
the minimum saccharide ligand N-acetyllactosamine- a common disaccharide found on 
many cellular glycoproteins-individual galectins can also recognize different 
modifications to this minimum saccharide ligand and so examine the fine specificity of 
certain galectins for tissue- or developmentally-specific ligands [29]. Location studies of 
galectins have established that these proteins can isolate into multiple cell compartments 
in function of the status of the cells in question [30, 31]. Although galectins as a whole do 
not have the signal sequence required for protein secretion through the usual secretory 
pathway, some galectins are secreted and are found in the extracellular zone [32]. 
 
2.5 Galectin-1: 
Galectin-1, a ubiquitous member of the galectin family, binds favourably N-
acetyllactosamine but can also obligate a variety of β-galactosamides with modifications 
in the non-reducing end, the glycosidic linkage, or even longer oligosaccharides [33-36]. 
Galectin-1 acts as a noncovalent homodimer [34], in which each monomer is formed by 
11 antiparallel β-strands generating a β-sandwich, with one CRD per monomer. The 
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galectin-1 CRDs carry the following residues: His-44, Asn-46, Arg-48, His-52, Asn-61, 
Trp-68, Glu-71, and Arg-73.  
Galectin-1 is presented in the thymus and by lymphoid parenchymal epithelial cells, 
endothelial cells, trophoblasts, activated T and B cells, macrophages, follicular DCs, and 
CD4+ CD25+ regulatory T cells.[20, 37-41, 21]. Within subtypes of CD4+ T cells, 
galectin-1 is highly expressed and secreted by TH1 cells [42]. Significant expression of 
galectin-1 is found in the lamina muscularis mucosae, just beneath the epithelium and the 
lamina propria, where HIV-1 prone CD4+ T cells can be found [19, 43, 44] galectin-1 
expression is intense in HIV-1-infected CD4+ T cells compared to non-infected by 
stander cells or untreated cells. [45]        
Recently experimented that galectin- 1, but not galectin-3, strongly binds to recombinant 
CD4, the main host receptor for HIV-1. Further, galectin-1 increases HIV-1 binding to 
CD4- expressing cells [16]. Thus, the discriminating recognition of CD4 by galectin-1 
but not galectin-3 is likely due to the difference in their binding preferences for bi-
antennary complex-type glycans presented on the surface of CD4. 
Thus, while further studies are justified, galectin-1 can be listed as one potential host 
factor that could directly help to HIV-1 transmission. 
2.6 Galectin-1 Inhibitors: 
Galectin-1 directly binds to HIV-1 virus particles. These activities of galectin-1 in HIV-1 
infection are inhibited by lactose, a β-galactoside-containing saccharide, but not mannose, 
confirming that galectin-1 distinguish β-galactoside residues expressed on HIV-1 [14-17]. 
HIV-1 entry strictly relies on the interaction between gp120 and CD4/coreceptor, 
pointing that galectin-1 only assists the initial virus binding event without affecting the 
rest of the HIV-1 entry process. Therefore, we endeavoured to find synthetic compounds 
derived from the lactoside or galactoside molecule that could specifically inhibit galectin-
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1 activity in a cellular model of HIV-1 infection by altering their attached aglycone 




Figure 2. Galectin-1–mediated HIV-1 adhesion to CD4+ T cells [57] 







2.7 Computer Aided Drug Discovery (CADD): 
Computational techniques in drug discovery and development process is rapidly 
acquiring in popularity, implementation and appreciation. Different terms are being 
applied to this area, including computer-aided drug design (CADD), computational 
drug design, computer-aided molecular design (CAMD), computer-aided molecular 
modeling (CAMM), rational drug design, in silico drug design, computer-aided 
rational drug design. Term Computer-Aided Drug Discovery and Development 
(CADDD) [58]. 
Fast expansion in this area has been made possible by advances in software and 
hardware computational power and sophistication, identification of molecular targets, 
and an increasing database of publicly available target protein structures. CADDD is 
being utilized to identify hits (active drug candidates), select leads (most likely 
candidates for further evaluation), and optimize leads i.e. transform biologically 
active compounds into suitable drugs by improving their physicochemical, 
pharmaceutical, ADMET/PK (pharmacokinetic) properties. Virtual screening is used 
to discover new drug candidates from different chemical scaffolds by searching 
commercial, public, or private 3-dimensional chemical structure databases. It is 
intended to reduce the size of chemical space and thereby allow focus on more 
promising candidates for lead discovery and optimization. The goal is to enrich set of 
molecules with desirable properties (active, drug-like, lead-like) and eliminate 
compounds with undesirable properties (inactive, reactive, toxic, poor ADMET/PK). 
In another words, in silico modelling is used to significantly minimize time and 
resource requirements of chemical synthesis and biological testing [59]. 
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Applications and benefits of CADDD have been reviewed and demonstrated in 
growing number of publications and supported by examples of drugs derived from the 
in silico approach [59–65]. Virtual screening has been shown more efficient than 
commonly used empirical screening. Shoichet reported that ligand discovery i.e. hit 
rates (number of compounds binding to a target divided by number of compounds 
tested) is greater in virtual screening by 2 or 3 orders of magnitude than in empirical 
screening [66]. 
Pharmacophore library screening followed by docking represent complimentary 
screening methods (Figure 3) with the combination allowing optimum results [59]. 
Commonly, this screening approach is introduced by a prior filtering of virtual 
databases (e.g. physicochemical, ADMET/ PK, stability, reactivity, toxicity, drug-like 
properties, etc.) [59, 67–71]. This combination of screening methods has been 
successfully employed in designing new hits and leads. 
Typically, this approach involves virtual screening (pharmacophore plus docking) of 
virtual chemical structure libraries containing hundreds of thousands of compounds. 


















































3.1 BIOINFORMATICS TOOLS & SOFTWARES: 
1. National Cancer Institute Open Database Compounds-Release 4 File Series - May 
2012  
2. Developmental Therapeutics Program NCI/NIH  
3. LigandScout v3.1 software  
4. Protein Data Bank (PDB) 
5. Chimera v1.8 software  
6. GROMACS software v4.6.5  
7. National Center for Biotechnology Information  (NCBI) 
8. Autodock-Vina  
9. MGL Tools v1.5.6  
10. LigPlot+  v1.4.5 software  
11. CHEMBL database  
12. McQSAR software  
13. PaDEL-Descriptor  
 
3.2 PREPARATION OF SMALL MOLECULES LIBRARY:  
Compound library database was downloaded from National Cancer Institute Open Database 
Compounds-Release 4 File Series - May 2012 [72] as provided by Developmental 
Therapeutics Program NCI/NIH (http://dtp.nci.nih.gov/). Open NCI database contained 
265,242 structures in SDF format. This SDF format file was processed in LigandScout 
accessible format (.ldb format), using LigandScout v3.1 software [73]. LigandScout provides 
two type of confirmation analysis: Omega FAST and Omega BEST quality analysis. Here we 





3.3 GENERATION OF STRUCTURE-BASED PHARMACOPHORE MODEL: 
Pharmacophore modeling is one of the most frequently applied and valuable methods of 
discovering novel scaffolds for various targets, so this approach was used in this work to find 
novel inhibitors of Galectin 1. Two different types of pharmacophore procedures can be used 
to discover the most potent leads: (i) structure-based and (ii) ligand-based. Here we used 
structure-based pharmacophore generation, which depends protein-ligand/inhibitor complex 
structure. The protein complex (receptor) was selected from the Protein Data Bank [74] to 
generate pharmacophore model. Many Galectin 1 complexes have been reported; among 
Galectin-1 and thiodigalactoside complex (PDB ID: 3OYW, Figure 4) was selected as the 
receptor based on the resolution of the complex as well as the deposited date. Protein-ligand 
complex was submitted to LigandScout vs.3.1 software and it present protein and ligand 
interaction as well as excluded volume of 3D structure of protein. LigandScout automatically 
generated pharmacophore model which showed total 21 chemical features, e.g. hydrogen 
bond donor (HBD) and hydrogen bond acceptor (HBA). We defined phrarmacophore 
hypothesis that contain 6 feature (2HBD & 4HBA).  
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Figure 4. Crystal structure of human galectin-1 in complex with thiodigalactoside [74]. 
 
3.4 PHARMACOPHORE-BASED VIRTUAL SCREENING: 
Selected pharmacophore hypothesis was used for virtual screening to retrieve a novel 
compound for Gal-1 inhibition from NCI database (2, 46,274 compounds). The screened 
compounds were filtered based on pharmacophore fit-score (≥60) and activity. The screened 
hits that satisfied the filter were selected for molecular docking studies to obtain the 






3.5 PREPARING THE RECEPTORS:  
Galectin-1 (receptor) complex with inhibitors e.g. lactose (1W6O), galactose(1W6M), N-
acetyllactosamine (1W6P), thiodigalactoside (3OYW) was downloaded from Protein Data 
Bank. We used 1W6O x-ray crystallographic structure with higher resolution 1.90A0 for 
molecular docking. Protein was visualized and ligands were removed using Chimera v1.8 
software [75]. We also edited (renumber from 1) and minimized the structure in Chimera 
v1.8 software. We performed protein energy minimization and simulation using GROMACS 
[76] software v4.6.5. 
 
3.5 BINDING SITE PREDICTION: 
Gal-1 carbohydrate recognition domain’s (CRD) residues was preferable target. Gal-1 CRD 
contain: His-44, Asn-46, Arg-48, His-52, Asn-61, Trp-68, Glu-71, and Arg-73 which was 
confirmed from literature and using National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/). We kept Arg-48 as center residue in grid box and started 
molecular docking.  
 
3.6 MOLECULAR DOCKING: 
Molecular docking is one of the best methods used in the structure based drug design process. 
Hence, docking was carried out, using Autodock-Vina v1.2 [77] to find the most suitable 
orientation and interactions (hydrogen bonds and hydrophobic interactions) of each lead at 
the protein’s active residues. The Protein-ligand complex were visualized in Chimera vs1.8 
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software [75]. Further, the grid was set with co-ordinates x=4.584, y=55.058, z=16.511 and 
volume 40*40*40. Maximum 20 number of mode was defined. The automated docking 
method was performed and docked molecules were filtered based on binding energy (> 7.0 
Kcal/mol) and then analyzed. 
 
3.7 DOCKING ANALYSIS: 
Protein and ligands interaction were analyzed, using MGL Tools 1.5.6 
(http://mgltools.scripps.edu/downloads/MGLTools-1.5.6/) Vina output file were loaded in 
analysis window of MGL tool software followed by macromolecule. Then we have seen 
hydrogen bond and hydrophobic interactions between macromolecule’s residues and ligands 
for each 20 clusters.  After that we plotted 2D image of best docked results using LigPlot+ 
[78] v 1.4.5 software. 
 
3.8 QSAR STUDIES: 
Quantitative Structure-Activity Relation (QSAR) studies was performed in McQSAR 
software [80]. For QSAR, we defined training and test set molecules. 35 compounds with 
experimental activity values e.g. IC50 were found and downloaded from CHEMBL database 
[79]. LigandScout software were used to cluster the 35 compounds and chose as training. 
Molecular descriptor for training set and test set compounds were generated using PaDEL-
Descriptor [81].These training and test set descriptors were further used to build and correlate 
the QSAR model, using McQSAR software. Total 316 filtered dock molecules was used as 
query test set compounds. Then we predicted structure activity relationship (SAR) for test set 































4.1 GENERATION OF STRUCTURE BASED PHARMACOPHORE MODEL: 
These days computer aided drug discovery is faster growing research field which escape hard 
work and save our time. CADD contain many tools and technologies, one of them is 
pharmacophore modelling. Pharmacophore model represent drug like chemical features 
(HBD, HBA, hydrophobic properties, aromatics group, polar charged group etc.). Gal-1 and 
thiodigalactoside complex x-ray crystallographic structure (3OYW) was submitted in 
LigandScout software and automatically structure based pharmacophore was generated. The 
generated pharmacophore having 21 chemical features (HBD & HBA) and exclusion volume. 
We removed exclusion volume and built a phamacophore hypothesis with 6 pharmacophoric 
features (2HBD +4HBA) [figure 5a, b, & c]. The pharmacophore hypothesis was validated 
by analysing the tolerance and Cartesian coordinates of pharmacophoric features (Table-1).   
 
 







Figure 5a b & c. Pharmacophore Hypothesis with selected 6 chemical features (Red = 
HBA: Hydrogen bond acceptor & Green = HBD: Hydrogen bond donor) 
 








1 HBA 22.92,4.33,14.05 21.10,2.37,16.31 1.5 1.0 
2 HBA 21.63,-0.07,14.75 21.97,0.13,17.74 1.5 1.0 
3 HBA 21.27,-1.71,21.04 19.49,-0.52,19.06 1.5 1.0 
4 HBA 17.49,-0.66,21.09 19.49,-0.52,19.06 1.5 1.0 
5 HBD 19.49,-0.52,19.06 21.27,-1.71,21.04 1.5 1.0 




4.2 PHARMACOPHORE BASED VIRTUAL SCREENING: 
Many compound databases (e.g. DrugBank, PubChem,CHEMBL and NCI etc.) are freely 
available. We preferred and downloaded NCI database which contain anti-cancerous and 
anti-HIV compounds. We processed database in LigandScout accessible file format, using 
LigandScout v3.1 software. We applied Omega FAST setting (Figure 6), that generate 
maximum 25 confirmations of molecules. Then we screened NCI database with our 
pharmacophore hypothesis. Pharmacophore based virtual sceening of NCI database have 
given total 2233 hits out of 2, 46, 274 active compounds. These 2233 hits had good 
pharmacophore score (PS≥60) (Table-2). We used all 2233 hits for molecular docking 
studies. 
 
                  




Table 2. NCI Database Hits with good pharmacophore score (PS≥60).     
                                                                           








































































































   








































































































      








































































































    








































































































    








































































































    








































































































    








































































































    








































































































     








































































































    








































































































    








































































































    








































































































    








































































































    








































































































    








































































































    








































































































    








































































































    








































































































   








































































































     








































































































    








































































































    


















































































































































4.3 PREPARING THE RECEPTOR: 
For docking studies, X-ray crystallographic structure of galectin-1 protein with higher 
resolution was downloaded from protein data bank e.g. PDB ID 1W6O & resolution1.90 A0. 
Gal-1 is homodimer with chain A & B and bulky protein. So we selected gal-1 chain A and 
removed chain B using chimera software. Then protein was given as input file in Gromacs for 
energy minimization and simulation. We applied Gromacs96 43a1 force field and simulated 
in water environment. Total 5156 water molecules were added to the system. We used 
steepest descent algorithm with tolerance (Fmax) 1.00000e+03 and number of steps 
50000.Our protein’s lowest energy coordinates were generated with steepest descents 
converged to Fmax < 1000 in 249 steps. And 249 steps have completed in 248.00 ps with  
-244279 kcal/mol average potential energy (Figure 7). 
 
Figure 7. Protein energy minimization using Gromacs v 4.5.6 
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4.4 BINDING SITE PREDICTION: 
Binding sites were obtained from literature and also predicted from NCBI website. After 
submitting PDB ID 1W6O in NCBI, we found sugar binding sites residues that also mention 
as carbohydrate recognition domain (CRD) residues in literature. These conserved domain 
residues are His-44, Asn-46, Arg-48, His-52, Asn-61, Trp-68, Glu-71, and Arg-73 (Figure 8). 
NCBI result of 1W6O. 
Chain A, X-Ray Crystal Structure Of C2s Human Galectin-1 complexed with Lactose 
ORIGIN       
        1 asglvasnln lkpgexlrvr gevapdaksf vlnlgkdsnn lclhfnprfn ahgdantivc 
       61 nskddgawgt eqreavfpfq pgsvaevcit fdqanltvkl pdgyefkfpn rlnleainym 






















4.5 MOLECULAR DOCKING: 
Molecular docking was performed to observe the small molecular affinity and interaction 
with CRD residue. All database hits were docked into identified carbohydrate recognition 
domain, using automated Autodock_Vina program. Molecular docking results were used to 
post- docking filter to select the compounds those binding energy was ≥-7.0Kcal/mol.316 
compounds out of 2233 docked hits were filtered and used for further analysis (Table-3).  
4.6 DOCKING ANALYSIS: 
 MGLTools v1.5.6 provide autodock vina results analysis program. The graphical 
presentation of docked confirmation of compounds were analysed for all 20 clusters. The 
clustering define interaction between active site residues of macromolecule and ligand. Based 
on number of cluster, docked results were further filtered. Those compound had ≥13 clusters 
out of 20 were selected. Finally, those compounds with binding affinity ≥-8.0Kcal/mol and 
cluster ≥ 13 considered as best compounds. We found 6 compounds, those fulfilled the both 
parameters are NCI_HITS 50, 379, 592, 1713, 1938 & 1992 (Table-6). In LigPlot+ analysis, 
6 best compounds named NSC4320, NSC95099, NSC140924, NSC641818, NSC683367, and 
NSC694346 were shown H-bond and hydrophobic interaction with CRD residues : His-44, 








Table: 3 Binding energy calculation of hits (≥-7.0Kcal/mol) 
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Figure 9. Galectin-1 and ligand interaction analysis using LigPlot+ v1.4.5 
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4.7 QSAR STUDIES:  
Quantitative Structure-Activity Relationship (QSAR) is used to build mathematical models 
for bioactivity prediction. Any QSAR model for given set of molecules correlates the 
activities with properties inherent to each molecule in the set itself. 35 compounds of 
CHEMBL database with known IC50 values were used to generate independent training and 
test data sets. Initially, all 35 compounds were clustered and defined as training sets, using 
LigandScout software. 7 cluster were formed and 28 considered as training set (Figure 10). 
Training set and test set descriptors, generated by PaDEL Descriptor software were used to 
construct and cross validate the QSAR model. QSAR model equation with best score (q2) 
and correlation (r2) value of the fits were reported (Table 4). The QSAR model equation was 
validated with experimental IC50 values of training set (Table 5) (Figure 11) and then, used 
for the prediction of activities of test set compounds (Table 6). 
 




Table 4. QSAR equation generation 
QSAR Model Best correlation 
(r2 ) 
Best score (q2) 



















mul= multiplication, plus= addition, const= constant, neg= negation, sqrt= squareroot,  
spline(knot,descriptor_name)= returns the value substracted by knot value, nssCH2= count of 
atom-type E-state: -CH2-, qspline= quadraticspline, lipoaffinityindex= lipoaffinity index, 
gauss= Gaussian function in 1D, RotBFrac= rotatable bond count.   
 
Table 5. QSAR Model Validation 












































   
 


























































    








1 50   
 
4320 -8.0  18 8.537486 
2 379  
 
95099 -8.1  14 7.612021 
3 592  
 
140924 -8.7  20 18.053857 
4 1713  
 
641818 -8.2  17 8.623231 
5 1938  
 
683367 -9.0  13 8.033781 
6 1992  
 


































Based on our results, we obtained 6 potential inhibitors of galectin-1 from NCI compound 
database. These molecules are named NSC4320, NSC95099, NSC140924, NSC641818, 
NSC683367 and NSC694346 having good binding energy (≥ -8.0 Kcal/mol) with better 
cluster (≥ 13). Our inhibitors preferably interacted with galectin-1 carbohydrate recognition 
domain residues that play major roles in adherence between HIV-1 capsid protein (gp120) 
and CD4+ helper T cells. We also predicted inhibitory concentration (IC50) of inhibitors 
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